Skip to main content
. 2019 Jul 1;179(9):1230–1239. doi: 10.1001/jamainternmed.2019.1758

Table 1. Characteristics of 638 856 Women Undergoing 1 693 163 Subsequent Digital Screening Mammograms Overall and by Invasive Breast Cancer and DCIS Status Within 1 Year of Follow-upa .

Characteristic Screening Mammograms, %
No Invasive Cancer or DCIS (n = 1 685 648) Invasive Cancer (n = 5326)b DCIS (n = 2189)b
Age, y
40-49 26.1 16.4 22.5
50-59 35.6 30.7 32.3
60-69 29.2 38.5 34.7
70-74 9.0 14.4 12.6
Race/ethnicity
White, non-Hispanic 67.0 73.3 66.2
Black, non-Hispanic 7.5 7.1 6.8
Asian, Native Hawaiian, or Pacific Islander 13.7 12.2 18.0
Hispanic 4.8 3.1 3.4
Other, mixed, or unknown 7.1 4.2 5.7
Menopausal status
Premenopausal or perimenopausal 29.8 20.7 26.2
Postmenopausal
Current HT use 7.3 9.9 7.7
No current HT use 53.6 58.1 55.9
Current HT use unknown 6.8 9.2 8.3
Surgical menopausal 2.5 2.1 1.9
Family history of breast cancerc 16.5 25.1 23.0
History of breast biopsy 19.9 37.4 35.9
BI-RADS breast density
Almost entirely fatty 10.9 7.1 5.7
Scattered areas of fibroglandular densities 42.1 41.3 38.6
Heterogeneously dense 38.9 43.4 45.2
Extremely dense 8.1 8.3 10.4
BI-RADS final assessment
Normal (1) 69.1 12.1 4.2
Normal, benign finding (2) 28.2 7.4 2.6
Probably benign (3) 1.7 4.2 5.5
Suspicious (4) 1.0 56.4 83.6
Malignant (5) 0 20.0 4.2
BCSC 5-y riskd
0% to <1.00%, low 29.6 14.1 18.2
1.00%-1.66%, average 40.1 34.8 36.6
1.67%-2.49%, intermediate 20.7 29.0 24.5
2.50%-3.99%, high 8.4 18.2 17.2
≥4.00%, very high 1.2 4.0 3.4

Abbreviations: BCSC, Breast Cancer Surveillance Consortium; BI-RADS, Breast Imaging Reporting and Data System; DCIS, ductal carcinoma in situ; HT, hormone therapy.

a

Subsequent screening examinations after recent prior mammogram within 9 to 30 months.

b

Invasive cancer cases and DCIS within 12 months of screening mammography.

c

Defined as first-degree relative (mother, sister, or daughter) with breast cancer.

d

The BCSC 5-year risk was calculated using age, race/ethnicity, first-degree family history of breast cancer, history of breast biopsy, and BI-RADS density.